Cervical Ca PROs in Clinical Practice
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03048435|
Recruitment Status : Active, not recruiting
First Posted : February 9, 2017
Last Update Posted : April 25, 2019
|Condition or disease||Intervention/treatment|
|Cervical Cancer Radiation Therapy||Other: EORTC QLQ CX-24 Other: Physician Feedback Form|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Feasibility and Acceptability of Measuring Cervical Cancer Specific Patient-Reported Outcomes in Clinical Practice|
|Actual Study Start Date :||February 27, 2017|
|Estimated Primary Completion Date :||November 2020|
|Estimated Study Completion Date :||November 2020|
Cervical Cancer Patients
Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
Other: EORTC QLQ CX-24
Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
Other Name: Quality of Life questionnaire
Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
Other: Physician Feedback Form
This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
- Percentage of EORTC QLQ CX24 questionnaire completed [ Time Frame: 9 months ]Gather information on feasibility of administering questionnaire
- Percentage of favorable scores (Agree or strongly agree) on Feedback Form [ Time Frame: 9 months ]Gather information on acceptability of incorporating the questionnaire in routine follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03048435
|Royal Victoria Regional Health Centre|
|Barrie, Ontario, Canada, L4M 6M2|
|Sunnybrook Research Institute|
|Toronto, Ontario, Canada, M4N 3M5|
|Princess Margaret Cancer Centre|
|Toronto, Ontario, Canada|
|Principal Investigator:||Jennifer Croke, MD||University Health Network--Princess Margaret Cancer Centre|